Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: Impact on the development of resistance

Drugs

Volumn 66, Issue 1, 2006, Pages 1-14

  Deryke, C Andrew ^a   Su, Young Lee ^a   Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM; CARBAPENEM; CEFEPIME; CEFMENOXIME; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; GARENOXACIN; GATIFLOXACIN; GENTAMICIN; GLYCOPEPTIDE; LEVOFLOXACIN; LINCOSAMIDE; LINEZOLID; MACROLIDE; METRONIDAZOLE; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAZOBACTAM; TELITHROMYCIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; CONCENTRATION RESPONSE; DATA ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFUSION; DRUG RESISTANCE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INFECTION; NEPHROTOXICITY; PREDICTION; REVIEW; TIME;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAM RESISTANCE; BETA-LACTAMS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS PNEUMONIAE;

NEGIBACTERIA; POSIBACTERIA;

EID: 31344476129     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666010-00001     Document Type: Review

References (70)

1. Clark NM, Patterson J, Lynch JP. Antimicrobial resistance among gram-negative organisms in the intensive care unit. Curr Opin Crit Care 2003; 9: 413-23
2. Bad bugs, no drugs. Statement from the Infectious Disease Society of America, 2004 Jul [online]. Available from URL: www.fda.gov/ohrms/dockets/ dockets/04s0233/04s-0233-c000005-03-IDSA-vol1.pdf [Accessed 2005 Jul 24]
3. Drusano GL. Antimicrobial pharmacodynamics: critical interac-tions of 'bug and drug'. Nat Rev Microbiol 2004; 2: 289-300
4. Deshpande LM, Fritsche TR, Jones RN. Molecular epidemiology of selected multidrug-resistant bacteria: a global report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2004; 49: 231-6
5. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003; 31: 481-98
6. Karlowsky JA, Thornsberry C, Jones ME, et al. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). Clin Infect Dis 2003; 36: 963-70
7. Chen DK, McGeer A, de Azavedo JC, et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada: Canadian Bacterial Surveillance Network. N Engl J Med 1999; 341: 233-9
8. Ho PL, Que TL, Tsang DN, et al. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1999; 43: 1310-3
9. Anderson KB, Tan JS, File TM, et al. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 2003; 37: 376-81
10. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 747-50
11. Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis 2004; 50: 59-69
12. Obritsch MD, Fish DN, MacLaren R, et al. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother 2004; 48: 4606-10
13. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34: 634-40
14. Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289: 885-8
15. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115: 585-90
16. Owens RC, Ambrose PG. Pharmacodynamics of quinolones. In: Nightingale CH, Marakawa T, Ambrose PG, editors. Antimi-crobial pharmacodynamics in theory and clinical practice. New York: Marcel Dekker Inc., 2002: 155-76
17. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10
18. Deziel-Evans LM, Murphy JE, Job ML. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clin Pharm 1986; 5: 319-24
19. Kashuba AD, Bertino JS, Nafziger AN. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms. Antimicrob Agents Chemother 1998; 42: 1842-4
20. Kashuba AD, Nafziger AN, Drusano GL, et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999; 43: 623-9
21. Prins JM, Buller HR, Kuijper EJ, et al. Once-daily gentamicin versus once-daily netilmicin in patients with serious infections: a randomized clinical trial. J Antimicrob Chemother 1994; 33: 823-35
22. Prins JM, Buller HR, Kuijper EJ, et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993; 341: 335-9
23. Rozdzinski E, Kern WV, Reichle A, et al. Once-daily versus thrice-daily dosing of netilmicin in combination with beta-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother 1993; 31: 585-98
24. Marik PE, Lipman J, Kobilski S, et al. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Chemother 1991; 28: 753-64
25. Nicolau DP, Wu AH, Finocchiaro S, et al. Once-daily aminoglycoside dosing: impact on requests and costs for therapeutic drug monitoring. Ther Drug Monit 1996; 18: 263-6
26. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279: 125-9
27. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-81
28. Drusano GL, Preston SL, Fowler C, et al. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004; 189: 1590-7
29. Ambrose PG, Grasela DM, Grasela TH, et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001; 45: 2793-7
30. Lim S, Bast D, McGeer A, et al. Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerg Infect Dis 2003; 9: 833-7
31. Allen GP, Kaatz GW, Rybak MJ. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003; 47: 2606-14
32. Smith HJ, Walters M, Hisanaga T, et al. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates. Antimicrob Agents Chemother 2004; 48: 3954-8
33. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003; 36: S42-50
34. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998; 27: 10-22
35. Schentag JJ, Smith IL, Swanson DJ, et al. Role for dual individualization with cefmenoxime. Am J Med 1984; 77: 43-50
36. Dagan R, Klugman KP, Craig WA, et al. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001; 47: 129-40
37. Tam VH, McKinnon PS, Akins RL, et al. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 2002; 50: 425-8
38. Lee SY, Kuti JK, Nicolau DP. Cefepime pharmacodynamics in patients with extended spectrum beta lactamases (ESBL) and non-ESBL infections [abstract no. A-1151]. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 16-19; Washington, DC
39. Nicolau DP, McNabb J, Lacy MK, et al. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001; 17: 497-504
40. Grant EM, Kuti JL, Nicolau DP, et al. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy 2002; 22: 471-83
41. Thalhammer F, Traunmuller F, El Menyawi I, et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 1999; 43: 523-7
42. Krueger WA, Bulitta J, Kinzig-Schippers M, et al. Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother 2005; 49: 1881-9
43. Tam VH, Louie A, Lomaestro BM, et al. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy 2003; 23: 291-5
44. Jumbe N, Louie A, Leary R, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003; 112: 275-85
45. Tam VH, Louie A, Deziel MR, et al. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. J Infect Dis 2005; 192: 420-8
46. Florea NR, Tessier PR, Zhang C, et al. Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae. Antimicrob Agents Chemother 2004; 48: 1215-21
47. DeRyke CA, Du X, Nicolau DP. Evaluation of bacterial kill when modeling the bronchopulomonary pharmacokinetic profile of moxifloxacin (MOX) and levofloxacin (LVX) against parC containing isolates of Streptococcus pneumoniae (SPN) [abstract no. A-453]. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 16-19; Washington, DC
48. Fux CA, Costerton JW, Stewart PS, et al. Survival strategies of infectious biofilms. Trends Microbiol 2005; 13: 34-40
49. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42: 521-7
50. Smith HJ, Nichol KA, Hoban DJ, et al. Stretching the mutant prevention concentration (MPC) beyond its limits. J Antimicrob Chemother 2003; 51: 1323-5
51. Blondeau JM, Zhao X, Hansen G, et al. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45: 433-8
52. Drlica K. The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 2003; 52: 11-7
53. Blondeau JM, Hansen G, Metzler K, et al. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J Chemother 2004; 16 Suppl. 3: 1-19
54. Guillemot D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998; 279: 365-70
55. Odenholt I, Gustafsson I, Lowdin E, et al. Suboptimal antibiotic dosage as a risk factor for selection of penicillin-resistant Streptococcus pneumoniae: in vitro kinetic model. Antimicrob Agents Chemother 2003; 47: 518-23
56. Knudsen JD, Odenholt I, Erlendsdottir H, et al. Selection of resistant Streptococcus pneumoniae during penicillin treatment in vitro and in three animal models. Antimicrob Agents Chemother 2003; 47: 2499-506
57. Ong CT, Tessier PR, Li C, et al. In vivo pharmacodynamic characterization of meropenem and its impact on the selection of resistance among Pseudomonas aeruginosa [abstract]. American College of Clinical Pharmacy Annual Meeting; 2003 Nov 2-5; Atlanta (GA)
58. Ong CT, Tessier PR, Li C, et al. Efflux pumps do not translate to in vivo failure in efficacy or emergence of resistance to meropenem, imipenem, or cefepime [abstract no. A-1867]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington, DC
59. Tam VH, Schilling AN, Melnick DA, et al. Comparison of betalactams in counter-selecting resistance of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2005; 52: 145-51
60. DeRyke CA, Kuti JK, Nicolau DP. Questioning the paradigm: monotherapy vs combination antimicrobial thearpy for treatment of Pseudomonas aeruginosa. Conn Med 2005; 69: 271-5
61. Bliziotis IA, Samonis G, Vardakas KZ, et al. Effect of aminoglycoside and beta-lactam combination therapy versus betalactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 2005; 41: 149-58
62. Carmeli Y, Troillet N, Eliopoulos GM, et al. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43: 1379-82
63. El Amari EB, Chamot E, Auckenthaler R, et al. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 2001; 33: 1859-64
64. Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 2003; 326: 1111
65. Drusano G, Louie A, Miller MH, et al. Prevention of the emergence of resistance in Pseudomonas aeruginosa infections through pharmacodynamic dosing and combination chemotherapy [abstract]. 98th International Conference of the American Thoracic Society; 2002 May 17-22; Atlanta (GA)
66. Drago L, De Vecchi E, Nicola L, et al. In vitro synergy and selection of resistance by fluoroquinolones plus amikacin or beta-lactams against extended-spectrum beta-lactamase-producing Escherichia coli. J Chemother 2005; 17: 46-53
67. Gerber AU, Vastola AP, Brandel J, et al. Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in an in vivo model. J Infect Dis 1982; 146: 691-7
68. Tam VH, Schilling AN, Neshat S, et al. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49: 4920-7
69. Allen GP. The mutant prevention concentration (MPC): a review. J Infect Dis Pharmacother 2003; 6: 27-47
70. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia: retrospective analysis of 410 episodes. Arch Intern Med 1985; 145: 1621-9